CRISPR Therapeutics CRSP Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's operating lease liabilities?
- CRISPR Therapeutics (CRSP) reported operating lease liabilities of $183.56M in Q1 2026.
- How has CRISPR Therapeutics's operating lease liabilities changed year-over-year?
- CRISPR Therapeutics's operating lease liabilities decreased by 9.1% year-over-year, from $201.85M to $183.56M.
- What is the long-term trend for CRISPR Therapeutics's operating lease liabilities?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's operating lease liabilities has grown at a 30.3% compound annual growth rate (CAGR), from $50.07M to $188.17M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.